Efficacy, safety and patient's satisfaction for treatment of genital psoriasis with tildrakizumab: a case series and review of literature.

Genital psoriasis (GenPs) leads to numerous symptoms such as itch, pain, burning and dyspareunia; however, it is often neglected by patients and physicians.1,2 Recently, two double-blind, placebo-controlled phase IIIb studies demonstrated superiority of ixekizumab over placebo for the treatment of moderate-to-severe GenPs,3 but there are few data on anti-IL-23. Sixty percentage of patients had severe psoriasis with PASI between 18 and 25; the remaining 40% of patients had moderate psoriasis with PASI between 10 and 12, the mean sPGA-G was 3.5. Genital psoriasis awareness program: physical and psychological care for patients with genital psoriasis. [Extracted from the article]